Annual report  
for the year ended 31 December 2025  
AKI Therapeutics A/S
Slotsmarken 12, 1., 2970 Hørsholm, Denmark
Registered number: 37 50 97 36
The annual report has been presented and adopted by the general meeting May 28th, 2026.  
Torsten Bjørn
Chairman of the general meeting  
 
Contents  
Page  
2
Company information  
Management's review  
3
4
Management's report  
Independent auditor's report  
Statement of comprehensive income  
Statement of financial position  
Statement of changes in equity  
Cash flow statement  
5
7
8
9
10  
11  
Notes  
1
 
Company information  
Executive management  
Board of directors  
Sigbjørn Georg Nielsen Kjærgård
Troels Peter Troelsen, chairman
Christian Vinding Thomsen
Lars Otto Uttenthal
Charlotte Pahl
Registered number  
Registered office  
37 50 97 36  
Slotsmarken 12, 1. th.  
2970 Hørsholm  
Denmark  
lndependent auditor  
Grant Thornton, Godkendt Revisionspartnerselskab
Lautrupgade 11
2100 København Ø
2
 
Management's review  
The Company’s principal activities  
AKI Therapeutics A/S is a preclinical biotechnological company that focuses 100% on developing an effective, specific  
treatment for acute kidney injury. The company’s drug candidate is an innovative concept within this treatment area,  
which presents one of the biggest and most important challenges in the field of current intensive medical care.  
There are currently no alternative treatments for acute kidney injury.  
Development in activities and financial matters  
There have been no significant changes in activities and financial matters.  
Financials  
The result for the year is a deficit of MDKK 1.59, which is in line with expectations in view of the Company's level of  
activity.  
3
 
Management's report  
The Board of Directors and the Executive management has today considered and approved the annual report of AKI  
Therapeutics A/S for the financial year 1 January - 31 December 2025.  
The Financial Statements have been prepared in accordance with the International Financial Reporting Standards (IFRS)  
as adopted by the EU and further requirements in the Danish Financial Statement Act.  
We consider the chosen accounting policy to be appropriate, and in our opinion the Financial Statements give a true  
and fair view of the financial position of the Company at 31 December 2025 and of the results of the Company's  
operations and cash flow for the financial year 1 January to 31 December 2025.  
Further, in our opinion, the management's review gives a true and fair view of the matters discussed in the  
management's review.  
We recommend that the annual report be approved at the annual general meeting.  
Hørsholm, May 8th., 2026  
Executive management  
Sigbjørn Georg Nielsen Kjærgård
Board of directors  
Troels Peter Troelsen
Chairman
Christian Vinding Thomsen
Charlotte Pahl
Lars Otto Uttenthal
4
 
Independent auditor’s report  
To the shareholders of AKl Therapeutics A/S  
Opinion  
We have audited the financial statements of AKI Therapeutics A/S for the financial year January 1 – December 31, 2025, which  
comprise statement of comprehensive income, statement of financial position, statement of changes in equity, statement of  
cash flows, accounting policies and notes. The financial statements are prepared in accordance with International Financial  
Reporting Standards as endorsed by the EU and further requirements in the Danish Financial Statements Act.  
In our opinion, the financial statements give a true and fair view of the financial position of the company at December 31, 2025  
and of the results of the company's operations and cash flows for the financial year January 1 – December 31, 205 in  
accordance with International Reporting Standards as issued by the International Accounting Standards Board (IASB) and  
adopted by the EU and additional requirements of the Danish Financial Statements Act.  
Basis for opinion  
We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements  
applicable in Denmark. Our responsibilities under those standards and requirements are further described in the section  
“Auditor’s responsibilities for the audit of the financial statements”. We are independent of the company in accordance with  
International Ethical requirements for auditors (IESBA’s Code of Ethics), and the additional requirements applicable in  
Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.  
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.  
Management's responsibilities for the financial statements  
Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the  
International Reporting Standards as adopted by EU and additional requirements Danish Financial Statements Act and for such  
internal control as Management determines is necessary to enable the preparation of financial statements that are free from  
material misstatement, whether due to fraud or error.  
In preparing the financial statements, Management is responsible for assessing the company's ability to continue as a going  
concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless  
Management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.  
Auditor’s responsibilities for the audit of the financial statements  
Our objectives are to obtain reasonable assurance about whether the financial statements, as a whole, are free from material  
misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance  
is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and additional  
requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from  
fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence  
the economic decisions of users taken on the basis of these financial statements.  
As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise  
professional judgment and maintain professional scepticism throughout the audit.  
5
 
Independent auditor’s report  
We also:  
Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design  
and perform audit procedures in responsive to those risks, and obtain audit evidence that is sufficient and appropriate to  
provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than one  
resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of  
internal control.  
●
●
Obtain an understanding of the internal control relevant to the audit in order to design audit procedures that are  
appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's  
internal control.  
●
●
Evaluate the appropriateness of accounting policies used by the management and the reasonableness of  
accounting estimates and related disclosures made by the management.  
Conclude on the appropriateness of the management’s use of the going concern basis of accounting in preparing the  
financial statements and based on the audit evidence obtained, weather a material uncertainty exists related to events or  
conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a  
material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the  
financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit  
evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the company  
to cease to continue as a going concern.  
●
Evaluate the overall presentation, structure and contents of the financial statments, including the disclosures, and  
whether the financial statements reflect the underlying transactions and events in a manner that gives a true and fair  
view.  
We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the  
audit and significant audit findings, including any significant deficiencies in the internal control that we identify during our  
audit.  
Statement on management's review  
Management is responsible for the management's Review.  
Our opinion on the financial statements does not cover the management’s Review, and we do not express any form of  
assurance conclusion thereon.  
In connection with our audit of the financial statements, our responsibility is to read the Management's Review and, in doing  
so, consider whether
Management's Review is materially inconsistent with the financial statements or knowledge obtained  
during the audit, or otherwise appears to be materially misstated.  
Moreover, it is our responsibility to consider whether the Management's Review provides the information required under the  
Danish Financial Statements Act.  
Based on the work we have performed, we conclude that Management's Review is in accordance with the financial statements  
and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any  
material misstatement of Management's Review.  
Copenhagen, May
8th., 2026  
Grant Thornton
Certified Public Accountants
Company reg. no. 34 20 99 36
Martin Bomholtz
State Authorised Public Accountant
mne34117
6
 
Statement of comprehensive income  
2025  
DKK  
2024  
DKK  
Note  
Revenue  
0
0
Cost of sales  
0
0
Gross profit  
0
0
3
3
-250.004
-617.469
-998.665
-543.092
Research and development costs  
Administrative costs  
Profit before depreciation,  
amortisation and impairment losses  
(EBITDA)  
-867.473
-1.541.757
Depreciation and amortisation of non-  
current assets  
6,7  
4
-364.586
-405.013
Operating profit (EBIT)  
-1.232.059
-1.946.770
Financial expenses  
-487.848
-280.695
Profit before tax  
-1.719.908
-2.227.464
5
Tax on profit for the year  
126.055
267.373
Net profit for the year  
-1.593.852
-1.960.091
Other comprehensive income  
0
0
Total comprehensive income  
-1.593.852
-1.960.091
7
 
Statement of financial position  
ASSETS  
31-12-2025  
DKK  
31-12-2024  
DKK  
Note  
Non-current assets  
6
7
Intangible assets  
Right-of-use assets  
729.608
610.019
802.569
694.582
Total non-current assets  
1.339.627
1.497.151
Current assets  
8, 9
Other receivables  
168.557
126.055
5.709
300.540
267.373
103.691
5
Current tax receivable  
10 Cash
and cash equivalents  
Total current assets  
300.321
671.604
Total assets  
1.639.948
2.168.755
EQUITY AND LIABILITIES  
DKK  
DKK  
Note  
Share capital  
525.000
525.000
Reserve for capitalised development costs  
Convertible instruments  
Retained earnings  
410.676
3.359.256
-3.743.033
451.744
2.020.265
-2.190.249
11 Total equity  
551.898
806.760
5
7
Provision for deferred tax  
0
0
Total provisions  
0
0
Lease liabilities  
309.523
352.431
Total long-term liabilities  
309.523
352.431
13 Trade
payables  
14 Other
liabilities  
391.727
386.799
581.674
427.890
Total current liabilities  
778.527
1.088.050  
1.639.948
1.009.564
1.361.995  
2.168.755
Total liabilities other than provisions  
Total equity and liabilities  
8
 
Statement of changes in equity  
Reserve for  
capitalised  
Convertible  
instruments  
development  
Share capital  
costs  
Retained earnings  
Total equity  
Statement of changes in equity  
01-01-2024 - 31-12-2024  
Equity as at 01-01-2024  
525.000
0
0
0
492.811
0
-271.225
746.586
-1.960.091
-1.960.091
Net profit for the year  
Convertible instruments  
Capitalised development costs  
0
0
2.020.265
0
0
0
2.020.265
0
-41.068
41.068
0
2.020.265  
-41.068  
-1.919.024  
60.174  
Dividends  
0
0
0
0
0
Transactions with owners  
0
0
0
0
0
Equity as at 31-12-2024  
525.000
2.020.265
451.744
-2.190.249
806.760
Statement of changes in equity  
01-01-2025 - 31-12-2025  
Equity as at 01-01-2025  
525.000
2.020.265
451.744
-2.190.249
-1.593.852
806.760
-1.593.852
1.763.990
-425.000
0
Net profit for the year  
Convertible instruments  
Convertible instruments, expenses  
Capitalised development costs  
0
0
0
0
0
1.763.990
-425.000
0
0
0
0
0
0
-41.068
41.068
0
1.338.990  
-41.068  
-1.552.785  
-254.862  
Dividends  
0
0
0
0
0
Transactions with owners  
0
0
0
0
0
Equity as at 31-12-2025  
525.000
3.359.256
410.676
-3.743.033
551.898
9
 
Cash flow statement  
31-12-2025  
DKK  
31-12-2024  
DKK  
Loss before tax  
-1.719.908
-2.227.464
Adjustment of non-cash transactions:  
72.961
0
280.695
Depreciation, amortisation and impairment losses, intangible assets  
72.961
0
487.848
Financial income  
Financial expenses  
Change in working capital:  
Receivables  
131.983
-114.428
Trade payables  
-189.946
0
565
267.373
64.466
0
3.737
283.593
Prepaid expenses  
Other liabilities  
Corporate tax  
Net cash from operating activities before net financials  
-949.124
-1.636.441
Financial income received  
Financial expenses paid  
0
0
-487.848
-280.695
Net cash from operating activities  
-1.436.972
-1.917.136
Repayment of loans  
Loans from shareholders  
Convertible instruments  
0
0
0
-225.000
2.020.265
1.338.990
Net cash received from financing activities  
Total cash flows for the year  
1.338.990
-97.982
1.795.265
-121.871
Cash equivalents beginning of year  
103.691
225.562
Cash equivalents end of year  
5.709
103.691
Cash and cash equivalents, end of year, comprises:  
Cash and cash equivalents  
5.709
103.691
Total  
5.709  
103.691  
10  
 
Notes  
1.  
2.  
3.  
4.  
5.  
6.  
7.  
8.  
9.  
Accounting policies  
Nature of operations  
Employee remuneration  
Financial income and expenses  
Tax  
Intangible assets  
Tangible assets and right-of-use assets  
Financial assets and liabilities  
Prepayments and other receivables  
10. Cash and cash equivalent  
11. Equity  
12. The company's funding for 2026  
13. Trade payables  
14. Other liabilities  
15. Contingent liabilities  
16. Operating lease commitments  
17. Financial risks and financial instruments  
18. Events occuring after the balance sheet date  
11  
 
Notes to the Financial Statements  
1. Accounting policies  
1.1 Basis of preparation  
The financial statements of AKI Therapeutics A/S have been prepared in accordance with International Financial  
Reporting Standards ("IFRS"), as adopted by the EU, IFRIC interpretations and with those parts of the Danish Financial  
Statements Act applicable to companies reporting under IFRS.  
IFRS is subject to amendment and interpretation by the IASB and the IFRS Interpretations Committee, and there is an on-  
going process of review and endorsement by the European Commission. These accounting policies comply with each  
IFRS that is mandatory for accounting periods ending on 31 December 2025.  
The preparation of the financial statements requires the making of estimates and judgements that effects the reporting  
of assets, liabilities and expenses. The estimates and judgments are reviewed on an ongoing basis. Estimates and  
judgements are based on historical results and on various other assumptions, which AKI Therapeutics believes to be  
resonable under the circumstances. However, the actual result may differ significantly from the estimates. We believe  
that the accounting policies relating to development costs and deferred taxes involve estimates or judgements that  
could affect the reported financial position and results.  
The financial statements have been prepared on the going concern basis and have been prepared under the historical  
cost convention as modified by the revaluation of financial assets and liabilities including derivative financial  
instruments. The principal accounting policies set out below have been consistently applied to all periods presented.  
1.2 Foreign currency translation  
Functional and presentation currency  
The Financial Statements are presented in currency DKK, which is also the functional currency of the Company.  
Foreign currency transactions and balances  
Foreign currency transactions are translated into the functional currency, using the exchange rates prevailing at the  
dates of the transactions (spot exchange rate). Foreign exchange gains and losses resulting from the settlement of such  
transactions and from the re-measurement of monetary items denominated in foreign currency at year-end exchange  
rates are recognised in profit or loss.  
Non-monetary items are not retranslated at year-end and are measured at historical cost (translated using the  
exchange rates at the transaction date), except for non-monetary items measured at fair value which are translated  
using the exchange rates at the date when fair value was determined.  
1.3 Revenue  
No revenue is recognized in the financial statements  
1.4 Reasearch and development costs  
Research and development costs primarily comprise internal and external costs related to development studies,  
employee costs and materials.  
1.5 Administrative costs  
Administrative costs comprise costs incurred during the year concerning management and administration, including  
costs concerning administrative staff, the executive board, office premises, stationery and office supplies.  
12  
 
1. Accounting policies - continued -  
Notes to the Financial Statements  
1.6 Net financials  
Net financials comprise interest, realised and unrealised capital gains and losses concerning financial assets and  
liabilities, amortisation of financial assets and liabilities, additions and reimbursements under the Danish tax  
prepayment scheme, etc. Financial income and expenses are recognised in the profit and loss account with the amounts  
that concerns the financial year.  
1.7 Intangible assets  
Finalized development projects  
Patents and development costs recognised in the balance sheet are measured at cost less accrued amortization and  
writedowns for impairment. Development projects are amortized according to the straight-line method over their  
estimated useful lives from the time when the asset is ready for use. Patents and finalized development projects are  
amortized over 15 year based on the remaining lifetime of the patent. Amortization methods, useful years and residual  
values are reviewed every year.  
Gain and loss from the sale of development projects, patents, and licenses are measured as the difference between the  
sales price with deduction of sales costs and the book value at the time of the sale. Gain or loss are recognised in the  
profit and loss account as other operating income or other operating expenses respectively.  
1.8 Right-of-use assets  
The Company assesses whether a contract is or contains a lease at inception of the contract. The Company recognizes  
right-of-use assets and corresponding lease liabilities at the lease commencement date, except for short-term leases  
and leases of low value. For these leases, lease payments is recognized as an operating expense on a straight-line basis  
over the term of the lease.  
The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liabilities adjusted for  
any lease payments made at or before the commencement date, plus initial costs incurred.  
The right-of-use assets are subsequently measured at cost less accumulated depreciation and impairment losses. The  
right-of-use assets are from the commencement date depreciated over the shorter period of lease term and useful life  
of the underlying asset. The estimated useful lives of right-of-use assets are determined on the same basis as those of  
the Company's corresponding assets such as property, plants and equipment. In addition, right-of-use assets are  
periodically reduced by impairment losses, if any, and adjusted in accordance with lease liabilities.  
The lease liabilities are initially measured at the present value of the lease payments that are not paid at the  
commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily  
determined, the Company's incremental borrowing rate.  
Lease payments included in the measurement of the lease liabilities comprise the following:  
-
-
-
-
Fixed payments.  
Variable payments, dependent on an index or rate.  
The exercise price of a purchase option if it is reasonably certain that the option will be exercized.  
Amounts expected to be payable under residual value guarantees.  
The lease liabilities are subsequently measured at amortized cost using the effectiv interest method. It is remeasured  
when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the  
estimate of the amount expected to be payable under a residual value guarantee, or if management changes its  
assessment of whether it will exercise a purchase, extension or termination option.  
When the lease liabilities are remeasured in this way, a corresponding adjustment is made to the carrying amount of  
the right-of-use assets, or is recorded in profit or loss if the carrying amount of the right-of-use assets has been reduced  
to zero.  
13  
 
1. Accounting policies - continued -  
Notes to the Financial Statements  
1.9 lmpairment testing of intangible assets and equipment  
The carrying amount of both intangible and tangible assets are subject to an annual impairment assesment in order to  
disclose any indication of impairment beyond those expresed by amortisation and depreciation.  
If indications of impairment are disclosed, impairment test are carried out for each individual asset or group of assets  
(cash-generating unit).  
An impairment loss is recognised for the amount by which the asset’s or cash-generating unit’s carrying amount  
exceeds its recoverable amount, which is the higher of fair value less costs to sell and value-in-use. To determine the  
value-in-use, management estimates expected future cash flows from each cash-generating unit and determines a  
suitable interest rate in order to calculate the present value of those cash flows. The data used for impairment testing  
procedures are directly linked to the Company’s latest approved budget, adjusted as necessary to exclude the effects of  
future reorganisations and asset enhancements. Discount factors are determined individually for each cash-generating  
unit and reflect management’s assessment of respective risk profiles, such as market and asset-specific risks factors.  
1.10 Financial instruments  
Recognition, initial measurement and de-recognition  
Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions  
of the financial instrument and are measured initially at fair value adjusted by transaction costs, except for those  
carried at fair value through profit or loss which are measured initially at fair value. Subsequent measurement of  
financial assets and financial liabilities are described below.  
Financial assets are derecognised when the contractual rights to the cash flows from the financial asset expire, or when  
the financial asset and all substantial risks and rewards are transferred. A financial liability is derecognised when it is  
extinguished, discharged, cancelled or expires.  
Classification and subsequent measurement of financial assets  
For the purpose of subsequent measurement, financial assets other than those designated and effective as hedging  
instruments are classified into the following categories upon initial recognition:  
●
loans and receivables (amortisized costs)  
●
financial assets at fair value through profit or loss (FVTPL)  
●
held-to-maturity (HTM) investments.  
All financial assets except for those at FVTPL are subject to review for impairment at least at each reporting date to  
identify whether there is any objective evidence that a financial asset or a group of financial assets is impaired. Different  
criteria to determine impairment are applied for each category of financial assets, which are described below.  
All income and expenses relating to financial assets that are recognised in profit or loss are presented within finance  
costs, finance income or other financial items, except for impairment of trade receivables which is presented within  
other expenses.  
14  
 
1. Accounting policies - continued -  
Notes to the Financial Statements  
Loans and receivables  
Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an  
active market. After initial recognition, these are measured at amortised cost using the effective interest method, less  
provision for impairment. Discounting is omitted where the effect of discounting is immaterial. The Company’s cash and  
cash equivalents, trade and most other receivables fall into this category of financial instruments.  
Individually significant receivables are considered for impairment when they are past due or when other objective  
evidence is received that a specific counterparty will default. Receivables that are not considered to be individually  
impaired are reviewed for impairment in groups, which are determined by reference to the industry and region of a  
counterparty and other shared credit risk characteristics. The impairment loss estimate is then based on recent  
historical counterparty default rates for each identified group.  
Financial assets at FVTPL  
A financial asset is classified at fair value through profit or loss if it is classified as held for trading or is designated as  
such upon initial recognition. Financial assets are designated at fair value through profit or loss if the Comapny manages  
such investments and makes purchase and sale decisions based on their fair value in accordance with the Company’s  
documented risk management or investment strategy. Upon initial recognition attributable transaction costs are  
recognised in profit or loss as incurred. Financial assets at fair value through profit or loss are measured at fair value,  
and changes therein are recognised in profit or loss.  
HTM investments  
HTM investments are non-derivative financial assets with fixed or determinable payments and fixed maturity other than  
loans and receivables. Investments are classified as HTM if the Company has the intention and ability to hold them until  
maturity. The Company do not currently hold any items designated into this category.  
HTM investments are measured subsequently at amortised cost using the effective interest method. If there is objective  
evidence that the investment is impaired, determined by reference to external credit ratings, the financial asset is  
measured at the present value of estimated future cash flows. Any changes to the carrying amount of the investment,  
including impairment losses, are recognised in profit or loss.  
1.11 lncome taxes  
Tax expense recognised in profit or loss comprises the sum of deferred tax and current tax not recognised in other  
comprehensive income or directly in equity.  
Current income tax assets and/or liabilities comprise those obligations to, or claims from, fiscal authorities relating to  
the current or prior reporting periods, that are unpaid at the reporting date. Current tax is payable on taxable profit,  
which differs from profit or loss in the Financial Statements. Calculation of current tax is based on tax rates and tax laws  
that have been enacted or substantively enacted by the end of the reporting period.  
Deferred income taxes are calculated using the liability method on temporary differences between the carrying  
amounts of assets and liabilities and their tax bases. However, deferred tax is not provided on the initial recognition of  
goodwill, or on the initial recognition of an asset or liability unless the related transaction is a business combination or  
affects tax or accounting profit. Deferred tax on temporary differences associated with investments in subsidiaries and  
joint ventures is not provided if reversal of these temporary differences can be controlled by the Group and it is  
probable that reversal will not occur in the foreseeable future.  
Deferred tax assets and liabilities are calculated, without discounting, at tax rates that are expected to apply to their  
respective period of realisation, provided they are enacted or substantively enacted by the end of the reporting period.  
15  
 
1. Accounting policies - continued -  
Notes to the Financial Statements  
Deferred tax assets are recognised to the extent that it is probable that they will be able to be utilised against future  
taxable income, based on the Company's forecast of future operating results which is adjusted for significant non-  
taxable income and expenses and specific limits to the use of any unused tax loss or credit. Deferred tax liabilities are  
always provided for in full.  
Deferred tax assets and liabilities are offset only when the Company has a right and intention to set off current tax  
assets and liabilities from the same taxation authority.  
Changes in deferred tax assets or liabilities are recognised as a component of tax income or expense in profit or loss,  
except where they relate to items that are recognised in other comprehensive income, or directly in equity, in which  
case the related deferred tax is also recognised in other comprehensive income or equity, respectively.  
1.12 Cash and cash equivalents  
Cash and cash equivalents comprise cash on hand and demand deposits, together with other short-term, highly liquid  
investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of  
changes in value.  
1.13 Equity, reserves and dividend payments  
Share capital represents the nominal value of shares that have been issued.  
Share premium includes any premiums received on issue of share capital. Any transaction costs associated with the  
issuing of shares are deducted from share premium, net of any related income tax benefits.  
Other components of equity include the following:  
Reserve for capitalised development costs - comprises other development projects.  
Retained earnings includes all current and prior period retained profits and share-based employee remuneration.  
Convertible instruments - see 1.14.  
All transactions with owners are recorded separately within equity.  
Dividend distributions payable to equity shareholders are included in other liabilities when the dividends have been  
approved in a general meeting prior to the reporting date.  
1.14 Convertible instruments  
The component parts of convertible loan notes issued by the company are classified separately as financial liabilities  
and equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability  
and an equity instrument. A conversion option that will be settled by the exchange of a fixed amount of cash or another  
financial asset for a fixed number of equity instruments issued by the company is an equity instrument.  
At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for a  
similar non-convertible instrument. This amount is recognised as a liability on an amortised cost basis using the effective  
interest method until extinguished upon conversion or at the instrument’s maturity date. The conversion option  
classified as equity is determined by deducting the amount of the liability component from the fair value of the  
compound instrument as a whole. This is recognised and included in equity and is not subsequently remeasured.  
In addition, the conversion option classified as equity will remain in equity until the conversion option is exercised, in  
which case the balance recognised in equity will be transferred to share capital/share premium. Convertible notes that  
will convert into a fixed number of equity shares results solely in an equity instruments and effectively treat the  
convertible note as prepaid equity. No gain or loss is recognised in profit or loss upon conversion or expiration of the  
conversion option.  
16  
 
1. Accounting policies - continued -  
Notes to the Financial Statements  
1.15 Provisions, contingent assets and contingent liabilities  
Provisions for legal disputes, onerous contracts or other claims are recognised when the Company has a present legal or  
constructive obligation as a result of a past event and it is probable that an outflow of economic resources will be  
required from the Company and amounts can be estimated reliably. Timing or amount of the outflow may still be  
uncertain.  
Provisions are measured at the estimated expenditure required to settle the present obligation, based on the most  
reliable evidence available at the reporting date, including the risks and uncertainties associated with the present  
obligation. Where there are a number of similar obligations, the likelihood that an outflow will be required in  
settlement is determined by considering the class of obligations as a whole. Provisions are discounted to their present  
values, where the time value of money is material.  
Any reimbursement that the Company can be virtually certain to collect from a third party with respect to the  
obligation is recognised as a separate asset. However, this asset may not exceed the amount of the related provision.  
In those cases where the possible outflow of economic resources as a result of present obligations is considered  
improbable or remote, no liability is recognised.  
1.16 Significant management judgement in applying accounting policies and estimation uncertainty  
When preparing the financial statements, management undertakes a number of judgements, estimates and  
assumptions about the recognition and measurement of assets, liabilities, income and expenses.  
Impairment assesment  
In assessing impairment, management estimates the recoverable amount of each asset or cash-generating units based  
on expected future cash flows and uses an interest rate to discount them. Estimation uncertainty relates to assumptions  
about future operating results and the determination of a suitable discount rate (see note 1.9).  
Useful lives of non-current assets  
Management reviews its estimate of the useful lives of intangible and tangible non-current assets at each reporting  
date, based on the expected utility of the assets. Uncertainties in these estimates relate to technical obsolescence that  
may change the utility of certain software application systems (development projects).  
2. Nature of operations  
AKI Therapeutics A/S is a preclinical biotechnological company that focuses 100% on developing an effective, specific  
treatment for acute kidney injury. The company’s drug candidate is a pioneering concept within this treatment area,  
which presents one of the biggest and most important challenges in the field of current intensive medical care.  
There are currently no alternative treatments.  
17  
 
Notes to the Financial Statements  
3. Employee remuneration  
2025  
2024  
Average number of employees in the year  
Number  
Number  
Directors  
1
1
Total  
1
1
2025  
DKK  
2024  
DKK  
Remuneration of Directors and the Board of Directors  
Remuneration of Directors  
0
0
Remuneration of the Board of Directors  
50.000  
50.000  
Total remuneration for Directors  
50.000  
50.000  
4. Financial income and expenses  
Financial expenses  
2025  
DKK  
2024  
DKK  
Interest expenses on liabilities measured at cost  
Interests etc, loan from shareholders  
Foreign exchange adjustments  
23.061  
464.444  
343  
26.258  
254.437  
0
Total  
487.848  
280.695  
2025  
DKK  
2024  
DKK  
5. Tax  
Tax on profit for the year:  
Current tax  
Change in deferred tax  
Deferred tax asset not capitalized  
-126.055  
-880.946  
880.946  
-267.373  
-539.878  
539.878  
Total  
-126.055  
-267.373  
Reconciliation of effective tax rate:  
Loss/Profit before tax  
-2.144.908  
-471.880  
345.824  
0
-2.227.464  
-490.042  
222.669  
0
Tax computed on the profit before tax at a tax rate of 22%  
Permanent differences and not capitalized tax asset  
Other adjustment to deferred tax  
Total - Effective tax rate (5,9%) (2024:12,%)  
-126.055  
-267.373  
18  
 
Notes to the Financial Statements  
31-12-2025  
DKK  
31-12-2024  
DKK  
Deferred tax is calculated as follows:  
Deferred taxes arising from temporary differences are summarised below:  
Intangible assets  
Taxable loss carried forward  
Deferred tax asset not capitalized  
160.514  
-1.041.460  
880.946  
183.022  
-722.899  
539.878  
Total deferred tax  
0
0
which is categorised as follows:  
Non-current deferred tax  
0
0
Current tax asset  
Tax reimbursement, calculated for the year  
126.055  
267.373  
Current tax asset, total  
126.055  
267.373  
6. lntangible assets  
Completed  
develop-  
ment  
Patents and  
licenses  
projects  
Total  
Financial year 2024  
Cost as at 01-01-2024  
333.997  
789.763  
1.123.759  
Cost as at 31-12-2024  
333.997  
789.763  
1.123.759  
Amortisation and impairment  
losses as at 01-01-2024  
Amortisation during the year  
Amortisation and impairment losses  
as at 31-12-2024  
90.277  
20.310  
157.953  
52.651  
248.230  
72.961  
110.587  
223.410  
210.604  
579.159  
321.191  
802.569  
Carrying amount as at 31-12-2024  
19  
 
Notes to the Financial Statements  
6. lntangible assets (continued)  
Completed  
develop-  
Patents and  
licenses  
ment  
projects  
Total  
Financial year 2025  
Cost as at 01-01-2025  
333.997  
789.763  
1.123.759  
Cost as at 31-12-2025  
333.997  
789.763  
1.123.759  
Amortisation and impairment  
losses as at 01-01-2025  
Amortisation during the year  
Amortisation and impairment losses  
as at 31-12-2025  
110.587  
20.310  
210.604  
52.651  
321.191  
72.961  
130.897  
203.100  
263.255  
526.508  
394.151  
729.608  
Carrying amount as at 31-12-2025  
All recognized intangible assets have definite useful lives.  
Pre-clinical programs  
During the financial year the Company has concluded a master service agreement with William Harvey Research  
Limited, a company under William Harvey Research Institute, covering the parties duties and obligations. WHRI is  
leading within research in kidney fysiology and fysiopathology.  
Further, the Company has established a Scientific Advisory Board wiith participation of professor Yaqoob and professor  
Thiemermann, both leading kidney experts at WHRI.  
During the financial year the Company obtained issuance of patent in Australia (patent no. 2018287044) on  
"Compositions for the prevention and treatment of acute renal injury ". The Company previously obtained patent in the  
USA (patent no. 11.471.445), Israel (patent no. 271564) and Canada (patent no. 3 067 911).  
Examination and defense of the Company’s patent applications in the other selected countries of the original filing  
continues.  
By the end of the financial year, the Company filed a new patent application "Compositions for improving and  
prolonging the viability and functionality of kidneys for transplantation during transport and storage ".  
20  
 
Notes to the financial statements  
7. Tangible assets and right-of-use assets  
Rent facilities  
Total  
Right-of-use assets and lease liabilities  
Cost as of January 1, 2024  
Additions during the year  
Depreciations during the year  
Right-of-use assets as of December 31, 2024  
422.156  
604.478  
-332.052  
694.582  
422.156  
604.478  
-332.052  
694.582  
Cost as of January 1, 2025  
Additions during the year  
Depreciations during the year  
Right-of-use assets as of December 31, 2025  
694.582  
207.062  
-291.626  
610.019  
694.582  
207.062  
-291.626  
610.019  
2025  
300.496  
309.523  
610.019  
2024  
342.152  
352.431  
694.582  
Lease liabilities  
Current  
Non-current  
Lease liabilities  
2025  
23.061  
2024  
26.258  
Amounts included in the income statement  
Interest expense leases  
Depreciation recognized on right-of-use assets  
Cost recognized for short term leases (less than 12 months)  
291.626  
314.687  
332.052  
358.310  
In 2025 the total cash outflow relating to leases was DKK 314.687, split between interests DKK 23.061 and repayment of  
DKK 291.626. In 2024 the total cash outflow realting to leases was DKK 358.310, split between interests DKK 26.258 and  
repayment of DKK 332.052.  
21  
 
Notes to the Financial Statements  
8. Financial assets and liabilities  
Note 1.10 provides a description of each category of financial assets and financial liabilities and the related accounting  
policies. The carrying amounts of financial assets and financial liabilities in each category are as follows:  
31 December 2025  
Loans and  
Held for  
trading  
(FVTPL)  
other  
receivables  
(carried at  
amortised  
cost)  
(carried at fair  
value)  
Total  
Financial assets  
Trade and other receivables  
Cash and cash equivalents  
0
0
294.612  
5.709  
294.612  
5.709  
Other short term financial assets  
Total financial assets  
0
0
300.321  
300.321  
300.321  
300.321  
Derivatives Other liabilities  
measured at fair  
value (carried at  
fair value)  
(carried at  
amortised  
cost)  
Total  
Financial liabilities  
Trade and other payables  
Long term liabilities  
0
0
778.527  
309.523  
778.527  
309.523  
Financial liabilities  
0
1.088.050  
1.088.050  
31 December 2024  
Loans and  
other  
receivables  
(carried at  
amortised  
cost)  
Held for  
trading  
(FVTPL)  
(carried at fair  
value)  
Total  
Financial assets  
Trade and other receivables  
Cash and cash equivalents  
0
0
617.913  
103.691  
617.913  
103.691  
Other short term financial assets  
Total financial assets  
0
0
721.604  
721.604  
721.604  
721.604  
22  
 
Notes to the Financial Statements  
8. Financial assets and liabilities - continued -  
31 December 2024  
Other  
liabilities  
(carried at  
amortised  
cost)  
Total  
Financial liabilities  
Trade and other payables  
Long term liabilities  
1.009.564  
352.431  
1.009.564  
352.431  
Financial liabilities  
1.361.995  
1.361.995  
Financial assets and liabilities measured at fair value, the methods used to measure fair value are described in  
accounting policies, note 1.10.  
All of the above financial assets and liabilities carrying values are approximate to their fair values due to their short term  
nature as at 31 December 2025 and 31 December 2024 with the exception of held for trading assets and derivative  
financial instruments which are carried at their fair values.  
9. Prepayments and other receivables  
31-12-2025  
DKK  
31-12-2024  
DKK  
Prepayments  
Accruals  
23.125  
0
0
0
Other receivables  
145.432  
300.540  
Financial assets  
168.557  
300.540  
10. Cash and cash equivalent  
31-12-2025  
DKK  
31-12-2024  
DKK  
Cash  
5.709  
103.691  
Total  
5.709  
103.691  
23  
 
Notes to the Financial Statements  
11. Equity  
Share capital  
The Company’s share capital consists of 5.250.000 ordinary shares of DKK 0,10 each. The shares are fully paid in. All  
shares are equally elligble to receive dividends and the repayment of capital and represent one vote at the  
shareholders’ meeting.  
Retained earnings  
Retained earnings represent retained profits.  
Reserve for capitalised development costs  
Reserve for capitalised development costs represent the development costs, recognised in the balance sheet, from  
January 1, 2016, less deferred tax.  
Convertible instruments  
The lenders and the Company have a mutual right to convert the instruments into shares in the Company to be execised  
in connection with the first coming capital increase.  
The instruments bear an interest of 3.0% per quarter of the actual balance of the instrument and a commitment fee of  
1.0% per quarter of the facility until the first coming capital increase at which the instruments mandatorily will be  
converted into new shares as described below.  
The instruments shall be converted into shares at a conversion rate of DKK 2.86 per share with a nominal value of DKK  
0.10 and by terms equal to other subscribers to the issue of shares. The new shares will be issued with the same rights  
as the existing shares.  
The convertible instruments are issued at market conformity.  
Capital management policies and procedures  
The Company's capital management objectives are to ensure its ability to continue as a going concern and to provide an  
adequate return to shareholders.  
The Company monitors capital on the basis of the carrying amount of equity plus borrowings, less cash and cash  
equivalents as presented on the statement of financial position.  
The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and  
the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may  
adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to  
reduce debt.  
12. The Company's funding for 2026  
Based on management's budget for 2026 AKI Therapeutics A/S has sufficient capital ressources to carry through the  
operational activities as planned for 2026. The capital ressources include a credit facility from Finansmanagement ApS.  
The Company expect to secure the necessary capital ressources through issuance of capital instruments.  
24  
 
Notes to the Financial Statements  
13. Trade payables  
31-12-2025  
DKK  
31-12-2024  
DKK  
Trade payables  
391.727  
581.674  
Trade and other paybles - current  
391.727  
581.674  
14. Other liabilities  
31-12-2025  
DKK  
31-12-2024  
DKK  
Taxes and other social securities  
Other liabilities  
Loan from shareholders  
Lease liabilities  
0
86.302  
0,00  
0
85.737  
0
300.496  
342.152  
Other liabilities - current  
15. Contingent liabilities  
386.799  
427.889  
Based on management's assesment, the Company is not involved in any lawsuites, arbitration cases or other matters  
which could have a material impact on the Company's financial position or result of operations (2024: DKK 0).  
16. Operating lease commitments  
The Company's annual rent obligation amounts to TDK 315 (2024: TDK 358).  
17. Financial risks and financial instruments  
Risk management policy  
Management manages the Company’s financial risks. The management of the Company's risks is included in the  
management's day-to-day monitoring of the Company. The Company is exposed to few financial risks, which result from  
its operating activities. The company does not actively engage in the trading of financial assets and financial derivatives.  
Credit risk  
Due to the nature of the business, credit risk is deemed minimal. The maximum credit risk relating to receivables  
corresponds to the carrying amount.  
lnterest rate risks  
The Company is only exposed to interest rate risks in connection with deficit liquidity, as the Company only have loans  
from shareholders, the risk is deemed minimal.  
Foreign currency risk  
The Company is subject to currency risks on payables and receivables in foreign currency, and purchases of services in  
foreign currency. The Company’s foreign trade is minimal.  
25  
 
Notes to the Financial Statements  
17. Financial risks and financial instruments - continued -  
Liquidity risk  
The Company liquidity risks covers the risk that the Company is not able to meet its liabilities as they fall due. The  
Company is not subject to material liquidity risks. Reference is made to the information in note 12.  
The maturities of financial liabilities appear from the tables below. All amounts are contractual cash flows, i.e. inclusive  
of interest.  
The Company has a satisfactory funding for 2026 to continue the operation of the Company as planned.  
Within 1 year  
1-2 year(s)  
2-5 years  
Over 5 years  
Total  
As at 1 January 2025  
Loan from shareholders  
Trade payables  
Other payables  
0
581.674  
427.889  
0
0
0
0
0
0
0
0
0
0
581.674  
427.889  
Total  
1.009.563  
0
0
0
1.009.563  
All financial liabilities as at 1 January 2025 are measured at amortised cost.  
Within 1 year  
1-2 year(s)  
2-5 years  
Over 5 years  
Total  
As at 31 December 2025  
Loan from shareholders  
Trade payables  
Other payables  
0
391.727  
386.799  
0
0
0
0
0
0
0
0
0
0
391.727  
386.799  
Total  
778.526  
0
0
0
778.526  
All financial liabilities as at 31 December 2025 are measured at amortised cost.  
18. Events occuring after the balance sheet date  
There were no post balance sheet events requiring adjustment to the Financial Statements.  
After the end of the financial year, the Company has entered into a Research Study Agreement with William Harvey  
Research Limited regarding extended animal studies on efficacy of the Company’s therapeutic conjugate in rats with  
ischemia/reperfusion-induced kidney injury (IRI).  
The study is planned to start in Q2-2026.  
After the end of the financial year, the Company has obtained issuance of patent in Europe (patent no. 3641798) issued  
as a unitary EU-patent with a combined validation in Spain and UK.  
After the end of the financial year, the Company has completed a capital increase in a combination of conversion of  
debt and cash subscription. The capital increase has strenghtened the Company's capital ressources.  
26  
 
Underskrifterne i dette dokument er juridisk bindende. Dokumentet er underskrevet via Penneo™ sikker  
digital underskrift. Underskrivernes identiteter er blevet registreret, og informationerne er listet herunder.  
“Med min underskrift bekræfter jeg indholdet og alle datoer i dette dokument.”  
På vegne af: AKI Therapeutics A/S  
Serienummer: 6bb7f296-4d57-43d8-b2ac-470932eb3a3f  
IP: 188.179.xxx.xxx  
På vegne af: AKI Therapeutics A/S  
Serienummer: 1472f427-285c-4a73-a4b4-f7f43e995071  
IP: 131.164.xxx.xxx  
2026-05-28 15:17:19 UTC  
2026-05-28 16:27:07 UTC  
Sigbjørn Georg Nielsen Kjærgård  
På vegne af: AKI Therapeutics A/S  
Serienummer: 29cc3928-e143-47f7-be20-a163dd10b9e3  
IP: 109.56.xxx.xxx  
På vegne af: AKI Therapeutics A/S  
Serienummer: eeda17cd-37e3-4213-8b48-19890c34d612  
IP: 37.49.xxx.xxx  
2026-05-28 17:05:59 UTC  
2026-05-29 06:44:57 UTC  
Martin Bomholtz  
Grant Thornton, Godkendt Revisionspartnerselskab CVR:  
Serienummer: 0cc06064-feb8-4906-be26-10d8062f97e3  
IP: 37.49.xxx.xxx  
På vegne af: Grant Thornton  
2026-05-29 09:51:18 UTC  
Serienummer: 07f98b67-f881-4b5f-ae57-2e18b964bfa1  
IP: 62.198.xxx.xxx  
2026-05-29 09:45:27 UTC  
Dettedokument er underskrevet digitaltviaPenneo.com. De underskrevne data  
er valideret vha. den matematiske hashværdi af det originale dokument. Alle  
kryptografiske beviser er indlejret i denne PDF for validering i fremtiden.  
Sådan kan du verificere, at dokumentet er originalt  
Når du åbner dokumentet i Adobe Reader, kan du se, at det er  
certificeret af Penneo A/S. Dettebeviser, at indholdet af dokumentet  
er uændret siden underskriftstidspunktet. Bevis for de individuelle  
underskriveres digitale underskrifter er vedhæftet dokumentet.  
Dette dokument er forseglet med et kvalificeret elektronisk segl. For mere  
information om Penneos kvalificeredetillidstjenester,se https://eutl.penneo.com.  
Du kan verificere de kryptografiske beviser vha. Penneos validator,  
https://penneo.com/validator, eller andrevalideringstjenester for  
digitale underskrifter.